Bibliographical noteFunding Information:
The SYNTAX Extended Survival study, which extended the follow-up up to 10 years, was supported by the German Foundation of Heart Research (Frankfurt am Main, Germany). The SYNTAX trial, covering the 0-5 year follow-up, was funded by Boston Scientific (Marlborough, MA, USA).
H. Hara reports a grant for studying overseas from the Japanese Circulation Society and a grant from the Fukada Foundation for Medical Technology. M.C. Morice is CEO and shareholder of CERC, a CRO not involved in this trial, and is a minor shareholder of ELECTRODUCER. A. Kappetein reports working as an employee of Medtronic, outside the submitted work. P.W. Serruys reports personal fees from Biosensors, Micel Technologies, Sinomedical Sciences Technology, Philips/Volcano, Xeltis, HeartFlow, and SMT outside the submitted work. The other authors have no conflicts of interest to declare.
© Europa Digital & Publishing 2022. All rights reserved.